PubMed:32179651 / 267-459 JSONTXT

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T4","span":{"begin":59,"end":62},"obj":"Glycan_Motif"},{"id":"T5","span":{"begin":91,"end":94},"obj":"Glycan_Motif"},{"id":"T6","span":{"begin":135,"end":138},"obj":"Glycan_Motif"}],"attributes":[{"id":"A4","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO"},{"id":"A5","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO"},{"id":"A6","pred":"image","subj":"T6","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00059MO"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T2","span":{"begin":59,"end":62},"obj":"http://www.glycoepitope.jp/epitopes/EP0071"},{"id":"T3","span":{"begin":91,"end":94},"obj":"http://www.glycoepitope.jp/epitopes/EP0071"},{"id":"T4","span":{"begin":135,"end":138},"obj":"http://www.glycoepitope.jp/epitopes/EP0071"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"sentences","denotations":[{"id":"T3","span":{"begin":0,"end":192},"obj":"Sentence"},{"id":"T3","span":{"begin":0,"end":192},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T4","span":{"begin":59,"end":62},"obj":"https://glytoucan.org/Structures/Glycans/G00059MO"},{"id":"T5","span":{"begin":91,"end":94},"obj":"https://glytoucan.org/Structures/Glycans/G00059MO"},{"id":"T6","span":{"begin":135,"end":138},"obj":"https://glytoucan.org/Structures/Glycans/G00059MO"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"mondo_disease","denotations":[{"id":"T3","span":{"begin":66,"end":79},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0010526"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T2","span":{"begin":59,"end":62},"obj":"Glycan"},{"id":"T3","span":{"begin":91,"end":94},"obj":"Glycan"},{"id":"T4","span":{"begin":135,"end":138},"obj":"Glycan"}],"attributes":[{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G00059MO"},{"id":"A24","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G00059MO"},{"id":"A25","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G00059MO"},{"id":"A26","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"GlyCosmos-GlycoEpitope","denotations":[{"id":"T2","span":{"begin":59,"end":62},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T3","span":{"begin":91,"end":94},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T4","span":{"begin":135,"end":138},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A2","pred":"glycoepitope_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0071"},{"id":"A3","pred":"glycoepitope_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0071"},{"id":"A4","pred":"glycoepitope_id","subj":"T4","obj":"http://www.glycoepitope.jp/epitopes/EP0071"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T3","span":{"begin":66,"end":79},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0010526"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"sentences","denotations":[{"id":"T3","span":{"begin":0,"end":192},"obj":"Sentence"},{"id":"T3","span":{"begin":0,"end":192},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T3","span":{"begin":0,"end":192},"obj":"Sentence"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T2","span":{"begin":59,"end":62},"obj":"Glycan"},{"id":"T3","span":{"begin":91,"end":94},"obj":"Glycan"},{"id":"T4","span":{"begin":135,"end":138},"obj":"Glycan"}],"attributes":[{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G00059MO"},{"id":"A24","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G00059MO"},{"id":"A25","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G00059MO"},{"id":"A26","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00059MO"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}

{"project":"GlyCosmos15-GlycoEpitope","denotations":[{"id":"T2","span":{"begin":59,"end":62},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T3","span":{"begin":91,"end":94},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T4","span":{"begin":135,"end":138},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A2","pred":"glycoepitope_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0071"},{"id":"A3","pred":"glycoepitope_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0071"},{"id":"A4","pred":"glycoepitope_id","subj":"T4","obj":"http://www.glycoepitope.jp/epitopes/EP0071"}],"text":"Recent studies have reported a structural heterogeneity of Gb3 in Fabry disease, including Gb3 isoforms with different fatty acids and Gb3 analogs with modifications on the sphingosine moiety."}